Stockscreener 앱 받기
55.17
0.18%
0.10
시간 외 거래:
55.18
0.010
+0.02%
전일 마감가:
$55.07
열려 있는:
$54.79
하루 거래량:
1.49M
Relative Volume:
1.15
시가총액:
$5.26B
수익:
$7.50M
순이익/손실:
$-345.91M
주가수익비율:
-12.65
EPS:
-4.3602
순현금흐름:
$-280.51M
1주 성능:
-4.72%
1개월 성능:
+28.06%
6개월 성능:
+49.31%
1년 성능:
+57.90%
1일 변동 폭
$54.40
$56.01
1주일 범위
$53.69
$59.00
52주 변동 폭
$26.74
$63.95
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
명칭
Xenon Pharmaceuticals Inc
전화
(604) 484-3300
주소
200 - 3650 GILMORE WAY, BURNABY
Compare XENE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
55.17 | 5.26B | 7.50M | -345.91M | -280.51M | -4.3602 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2025-09-03 | 재개 | Wells Fargo | Overweight |
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-01 | 개시 | H.C. Wainwright | Buy |
| 2024-01-04 | 개시 | Citigroup | Buy |
| 2023-12-08 | 개시 | Robert W. Baird | Outperform |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-04-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-14 | 개시 | Goldman | Buy |
| 2022-12-12 | 개시 | Cowen | Outperform |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-10-19 | 개시 | Raymond James | Outperform |
| 2022-08-29 | 개시 | BofA Securities | Buy |
| 2022-07-21 | 개시 | JP Morgan | Overweight |
| 2021-10-28 | 개시 | RBC Capital Mkts | Outperform |
| 2020-10-02 | 개시 | SVB Leerink | Outperform |
| 2020-07-21 | 개시 | Needham | Buy |
| 2020-06-01 | 재개 | Jefferies | Buy |
| 2020-03-25 | 개시 | Wedbush | Outperform |
| 2020-01-08 | 개시 | William Blair | Outperform |
| 2019-09-20 | 개시 | Guggenheim | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2017-03-13 | 개시 | Jefferies | Buy |
| 2016-10-21 | 개시 | Stifel | Buy |
| 2016-09-26 | 개시 | Guggenheim | Buy |
| 2016-04-14 | 재확인 | Jefferies | Buy |
| 2015-10-30 | 재개 | Jefferies | Buy |
| 2014-12-02 | 개시 | Canaccord Genuity | Buy |
모두보기
Xenon Pharmaceuticals Inc 주식(XENE)의 최신 뉴스
Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why - Yahoo Finance
Investors Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals (XENE) Is Down 6.7% After $650 Million Follow-On Offering And Phase 3 Epilepsy Win - Yahoo Finance
Assessing Xenon Pharmaceuticals (XENE) Valuation After Positive Phase 3 X TOLE2 Azetukalner Results - simplywall.st
XENE stock up as Azetukalner meets goal in focal onset seizures study - MSN
XENE Technical Analysis & Stock Price Forecast - Intellectia AI
Jain Global LLC Takes Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Inc. $XENE Shares Sold by Granahan Investment Management LLC - MarketBeat
Holocene Advisors LP Acquires 167,078 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Cinctive Capital Management LP Takes Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Inc. $XENE Shares Sold by Bamco Inc. NY - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by Brokerages - MarketBeat
XENE: Wedbush Adjusts Target Price for Xenon Pharmaceuticals | X - GuruFocus
Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Cut to $63.00 by Analysts at Wedbush - MarketBeat
Wedbush lowers Xenon Pharmaceuticals stock price target to $63 - Investing.com
HighVista Strategies LLC Increases Stock Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
5 Stocks Making Huge Moves this Week - Insider Monkey
Xenon Pharmaceuticals (XENE) Climbs 31.7% as Epilepsy Treatment Moves Forward - Insider Monkey
Commodore Capital LP Has $108.41 Million Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Sets Date for 2026 Annual Shareholder Meeting - The Globe and Mail
Xenon Pharmaceuticals Inc. Announces 2026 Annual Meeting of Shareholders Details and Notice Procedures - Minichart
Christopher John Kenney Sells 1,410 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) Stock - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) CEO Sells $403,620.84 in Stock - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Insider Andrea Difabio Sells 1,342 Shares - MarketBeat
XENE (NASDAQ: XENE) Rule 144 Notice — 3,750 RSUs Vesting - Stock Titan
Ian Mortimer sells 270,000 XENE shares; multiple disposals (NASDAQ: XENE) - Stock Titan
Xenon Pharmaceuticals closes $747.5M public offering By Investing.com - Investing.com Australia
Xenon Strengthens Balance Sheet With Major Equity Offering - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
Finance Watch: As IPO Market Quiets Again, Xenon, Dianthus Price Big Follow-Ons - Citeline News & Insights
Xenon Pharmaceuticals (XENE) sets June 2, 2026 annual shareholder meeting and April 7 record date - Stock Titan
Xenon Pharmaceuticals closes $747.5M public offering - Investing.com Nigeria
Xenon’s X-TOLE2 Trial Completion Puts XEN1101 in Focus for Epilepsy Investors - TipRanks
Xenon Pharmaceuticals (XENE) CEO reports RSU vesting and 7,308-share tax sale - Stock Titan
Xenon Pharmaceuticals closes US $747.5M public offering - Private Capital Journal
Assessing Xenon Pharmaceuticals (XENE) Valuation After A Sharp Recent Share Price Surge - Yahoo Finance
BofA raises Xenon Pharmaceuticals price target on trial success - Investing.com South Africa
BofA raises Xenon Pharmaceuticals price target on trial success By Investing.com - Investing.com Canada
Xenon Pharmaceuticals Closes $747.5 Million Public Offering - marketscreener.com
Xenon Pharmaceuticals Nets $707.7 Million in $57 Share Offering With Pre-Funded Warrants - TradingView
Xenon Pharmaceuticals (NASDAQ: XENE) prices $707.7M equity raise - Stock Titan
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares - GlobeNewswire
Xenon Pharmaceuticals launches $500 million stock offering By Investing.com - Investing.com Nigeria
The Azetukalner Breakthrough: A Deep Dive into Xenon Pharmaceuticals (XENE) - The Chronicle-Journal
Xenon Pharmaceuticals (NASDAQ: XENE) offers 10.5M shares and 877K warrants for $615M - Stock Titan
Is Xenon Pharmaceuticals (XENE) Pricing Look Compelling After Recent 37% Weekly Share Surge? - simplywall.st
What is HC Wainwright's Estimate for XENE FY2027 Earnings? - MarketBeat
Atika Capital Management LLC Invests $1.53 Million in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals shares jump 40% after strong Phase 3 seizure trial results - MSN
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares - Bitget
Xenon Raises $650 Million in Upsized U.S. Equity Offering - The Globe and Mail
Xenon Pharmaceuticals Inc (XENE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):